Drug Trial Radar · NCT06531824
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
8,371
Actual
Start
Aug 30, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.
Conditions
- Kidney Disease, Chronic
Interventions
BI 690517Drug
BI 690517 (called Type M randomized treatment)
Placebo matching BI 690517Drug
Placebo matching BI 690517
EmpagliflozinDrug
Empagliflozin (called Type E)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.Time frame: up to 4 years
Locations
562 sites in 20 countries. Site status is shown where the registry gives one.
Apogee Clinical Research
Huntsville, Alabama
Southwest Kidney Institute
Surprise, Arizona
National Heart Institute
Beverly Hills, California
Olive View - UCLA Medical Cente
Sylmar, California
Interventional Cardiology Medical Group
West Hills, California
South Denver Cardiology Associates
Littleton, Colorado
Flourish Research
Boca Raton, Florida
University of Florida Health Shands Hospital
Gainesville, Florida
Florida Kidney Physicians LLC
Jacksonville Beach, Florida
Total Research Group, LLC
Miami, Florida
Bioresearch Partner
Miami, Florida
Emory University School of Medicine
Atlanta, Georgia
Joseph Maxwell Cleland Atlanta VA Medical Center
Decatur, Georgia
East Coast Institute For Research LLC
Macon, Georgia
Kootenai Research Services
Coeur d'Alene, Idaho
Northwestern University
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Kansas Nephrology Research Institute, LLC
Wichita, Kansas
University of Louisville
Louisville, Kentucky
Medstar Health Research Institute
Baltimore, Maryland
Lake Michigan Nephrology
Saint Joseph, Michigan
St. Clair Nephrology Research, LLC
Shelby, Michigan
Minneapolis VA Health Care System
Minneapolis, Minnesota
Southwest Mississippi Nephrology, Pllc
Brookhaven, Mississippi
Great Plains Nephrology
North Platte, Nebraska
VA Southern Nevada Healthcare System
North Las Vegas, Nevada
Sierra Nevada Specialty Care
Reno, Nevada
Seacoast Kidney and Hypertension Specialists
Portsmouth, New Hampshire
Advanced Heart Care, LLC
Bridgewater, New Jersey
UNM Health Science Center
Albuquerque, New Mexico
VA New York Harbor Healthcare System
New York, New York
Metrolina Nephrology Associates, PA
Charlotte, North Carolina
Metrolina Nephrology Associates, PA
Charlotte, North Carolina
Carolina Kidney Associates
Greensboro, North Carolina
Brookview Hills Research Associates LLC
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Northeast Endocrine Metabolic Associates
Philadelphia, Pennsylvania
Temple University
Philadelphia, Pennsylvania
Clinical Renal Associates
Upland, Pennsylvania
Nephrology Associates, Inc
East Providence, Rhode Island
Showing 40 of 562 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.